DE1063234T1 - Hydrophobische Taxan Derivate - Google Patents

Hydrophobische Taxan Derivate

Info

Publication number
DE1063234T1
DE1063234T1 DE1063234T DE00121129T DE1063234T1 DE 1063234 T1 DE1063234 T1 DE 1063234T1 DE 1063234 T DE1063234 T DE 1063234T DE 00121129 T DE00121129 T DE 00121129T DE 1063234 T1 DE1063234 T1 DE 1063234T1
Authority
DE
Germany
Prior art keywords
taxane
derivative
carrier
lipid
hydrophobic organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1063234T
Other languages
English (en)
Other versions
DE10021129C2 (de
DE10021129A1 (de
Inventor
Designation Of The Inventor Has The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of DE1063234T1 publication Critical patent/DE1063234T1/de
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (3)

  1. Ansprüche
    Q-C(O)NHCH(C6H5)CH(OR)C(O)- besitzt; Q C6H5-, (CH3)3C-O- oder (CH3)CH = C(CH3)- ist;
    R und R1 jedes unabhängig entweder H oder hydrophobe organische Komponenten ausgewählt aus gesättigten oder ungesättigten aliphatischen oder verzweigten Fettsäuren ist und wobei wenigstens ein R oder R1 nicht H ist, wobei wenn R1 H ist, ist A1 eine Gruppe, die die Formel Q-C(O)NHCH(C6H5)CH(OR)C(O)- besitzt und R ist nicht H;
    wobei wenn A1 H ist oder wenn A1 eine Gruppe ist, die die Formel Q-C(O)NHCH(C6H5)CH(OR)C(O)- besitzt und R H ist, ist R1 nicht H.
    DE/EP1063234T1
    - 2-
  2. 2. Taxanderivat aus Anspruch 1, wobei R und R' ungesättigte aliphatische Fettsäuren sind.
  3. 3. Taxanderivat nach Anspruch 1, wobei das Taxanderivat mit einem Lipid verbunden ist und die Verbindung zwischen dem Taxan und dem Lipid durch die Anwesenheit der hydrophoben Fettsäuregruppen stabilisiert ist.
DE1063234T 1995-01-09 1996-01-11 Hydrophobische Taxan Derivate Pending DE1063234T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36981795A 1995-01-09 1995-01-09
US08/474,888 US5580899A (en) 1995-01-09 1995-06-07 Hydrophobic taxane derivatives

Publications (1)

Publication Number Publication Date
DE1063234T1 true DE1063234T1 (de) 2001-05-23

Family

ID=27004714

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69627722T Expired - Fee Related DE69627722T2 (de) 1995-01-09 1996-01-11 Hydrophobische Taxan Derivate
DE1063234T Pending DE1063234T1 (de) 1995-01-09 1996-01-11 Hydrophobische Taxan Derivate
DE69617203T Expired - Fee Related DE69617203T2 (de) 1995-01-09 1996-01-11 Hydrophobe taxan derivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69627722T Expired - Fee Related DE69627722T2 (de) 1995-01-09 1996-01-11 Hydrophobische Taxan Derivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69617203T Expired - Fee Related DE69617203T2 (de) 1995-01-09 1996-01-11 Hydrophobe taxan derivate

Country Status (13)

Country Link
US (4) US5580899A (de)
EP (2) EP0802911B1 (de)
JP (1) JPH11500712A (de)
KR (1) KR100386002B1 (de)
AT (2) ATE209196T1 (de)
AU (1) AU691401B2 (de)
CA (1) CA2209001C (de)
DE (3) DE69627722T2 (de)
DK (2) DK1063234T3 (de)
ES (2) ES2154622T3 (de)
GR (1) GR20010300005T1 (de)
PT (2) PT1063234E (de)
WO (1) WO1996021658A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
EP1229030B1 (de) * 1995-09-12 2005-11-09 Zeneus Pharma Limited Hydrolyse-einleitende hydrophobe Taxane Derivate
JP4192208B2 (ja) * 1995-09-12 2008-12-10 セファロン リミテッド 加水分解促進性のタキサン疎水性誘導体
US6667053B1 (en) * 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
NZ505584A (en) 1996-05-24 2002-04-26 Univ British Columbia Delivery of a therapeutic agent to the smooth muscle cells of a body passageway via an adventia
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6136988A (en) * 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
ATE297198T1 (de) * 1999-02-23 2005-06-15 Angiotech Int Ag Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen
US6191290B1 (en) * 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
KR20020000147A (ko) * 1999-03-09 2002-01-04 니겔 엘. 웹 지방산-항암제 결합체 및 그의 용도
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
HUP0202669A3 (en) * 1999-09-09 2004-06-28 Univ California Cationic liposome delivery of taxanes to angiogenic bloos vessels
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) * 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
EP1423107B1 (de) 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fettalkohol-arzneimittel-konjugate
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
US20030206893A1 (en) * 2002-05-06 2003-11-06 Sohail Malik Cell proliferating agents
WO2004069224A2 (en) 2003-02-03 2004-08-19 Neopharm, Inc. Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
JP5139814B2 (ja) * 2005-02-18 2013-02-06 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 医療装置に結合した改善された疎水性を有した薬剤
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2006110862A2 (en) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
EP1883627B1 (de) 2005-05-18 2018-04-18 Pharmascience Inc. An die bir-domäne bindende verbindungen
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
ES2535217T3 (es) * 2007-11-28 2015-05-07 Celator Pharmaceuticals, Inc. Sistema mejorado de administración de taxano
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
WO2011038278A2 (en) 2009-09-25 2011-03-31 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
CN103096874A (zh) * 2010-04-15 2013-05-08 华盛顿大学 前药组合物、前药纳米粒子及其使用方法
EP2566474B1 (de) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Nichtwässrige taxan-pro-emulsionsformulierungen sowie verfahren zu ihrer herstellung und verwendung
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US20140357706A1 (en) * 2011-10-13 2014-12-04 The Uab Research Foundation Stearate Compounds
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN105853403B (zh) * 2016-05-09 2019-03-29 上海天氏利医药科技有限公司 一种紫杉醇棕榈酸酯脂质体及其制备方法
WO2018078064A1 (en) * 2016-10-28 2018-05-03 Les Laboratoires Servier Liposomal formulation for use in the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
CA2023645C (fr) * 1989-08-23 2002-03-26 Jean-Noel Denis Procede pour la preparation enantioselective de derives de la phenylisoserine
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
FR2658510B1 (fr) * 1990-02-21 1992-04-30 Rhone Poulenc Sante Nouveau derive de la beta-phenylisoserine, sa preparation et son emploi.
FR2678930B1 (fr) * 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
FR2680506B1 (fr) * 1991-08-19 1994-09-02 Rhone Poulenc Rorer Sa Procede de preparation de derives de la beta-phenylisoserine et leur utilisation.
WO1993010076A1 (en) * 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
FR2687150B1 (fr) * 1992-02-07 1995-04-28 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives

Also Published As

Publication number Publication date
EP1063234A2 (de) 2000-12-27
AU4752296A (en) 1996-07-31
ES2163613T3 (es) 2002-02-01
DE69627722T2 (de) 2003-10-16
PT802911E (pt) 2002-05-31
AU691401B2 (en) 1998-05-14
US5580899A (en) 1996-12-03
US6291690B1 (en) 2001-09-18
WO1996021658A1 (en) 1996-07-18
US6118011A (en) 2000-09-12
EP0802911A1 (de) 1997-10-29
CA2209001C (en) 2007-12-18
DE69617203D1 (de) 2002-01-03
EP0802911B1 (de) 2001-11-21
DK1063234T3 (da) 2003-06-02
ATE238290T1 (de) 2003-05-15
DE69627722D1 (de) 2003-05-28
EP1063234B1 (de) 2003-04-23
JPH11500712A (ja) 1999-01-19
EP1063234A3 (de) 2001-04-11
ATE209196T1 (de) 2001-12-15
US5939567A (en) 1999-08-17
ES2154622T3 (es) 2003-09-16
ES2154622T1 (es) 2001-04-16
CA2209001A1 (en) 1996-07-18
PT1063234E (pt) 2003-09-30
KR19980701289A (ko) 1998-05-15
DK0802911T3 (da) 2002-05-21
GR20010300005T1 (en) 2001-02-28
DE69617203T2 (de) 2002-05-08
KR100386002B1 (ko) 2003-10-10

Similar Documents

Publication Publication Date Title
DE1063234T1 (de) Hydrophobische Taxan Derivate
DE69034194T2 (de) N-Acylderivate der Antitumor-Antibiotika vom Typ LL-E33288
DE3775882D1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
KR940703806A (ko) 20-메틸-치환된 비타민 D 유도체 (20-Methyl-Substituted Vitamin D Derivatives)
CZ85395A3 (en) Derivatives of vaprooic and 1-valproenic acids and pharmaceutical preparations based thereon
DE4126662A1 (de) Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
KR910002802A (ko) 1,2,3,4-테트라히드로-9-아크리딘아민의 유도체
DE69533267T2 (de) Colchicin-derivate sowie ihre therapeutische Verwendung
JPS5699485A (en) 66*11hydroxyethyl**22*aminoethylthio**1*11 disubstitutedd11carbadethiapenee22emm33carboxylic acids
DE59305012D1 (de) 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19547958A1 (de) Anthracyclin-Derivate
DE2907349C2 (de) Arzneimittel mit cytostatischer Wirksamkeit
DE69531586T2 (de) Immmunosuppressive Cyclolignanderivate
KR910000775A (ko) 무라밀 디펩티드 유도체
EP0112871A1 (de) Derivate des n.n-bis(2-chlor-äthyl)-phosphorsäureamids.
DE60003795T2 (de) Sulfofukosylacylglycerin-derivate und ihre anwendung als medikamente
AT398203B (de) Mitomycinphosphat-derivate
DE68924499T2 (de) Verfahren zur Herstellung von Phosphatidylcholin Derivaten.
DE3819634A1 (de) Neue aldophophamidglycoside, verfahren zu ihrer herstellung sowie ihre verwendung als pharmazeutische wirkstoffe
ATE25516T1 (de) Neue carbonsaeure-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
SE8204791L (sv) Sett att framstella alkoxivinkaminsyraestrar och alkoxiapovinkaminsyraestrar
DE4010097A1 (de) Ungesaettigte n-benzoxodiazolopyranyllactame, ihre herstellung und verwendung
ATE176480T1 (de) Verfahren zur stereoselektiven herstellung von semisynthetischen diastereomerenreinen n-glycidyl-anthracyclinen
DE3728915A1 (de) Substituierte phospholipidanaloge pantoinsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10035189A1 (de) Arzneimittel zur oralen Applikation mit einem Gehalt an 3-N-Formylhydroxylaminopropylphosphonsäureestern oder 3-N-Acetylhydroxylaminopropylphosphonsäureestern als Wirkstoff